Hanx Biopharma Prices HKEX IPO to Fund Bispecific Antibody Pipeline
CompanyDeals

Hanx Biopharma Prices HKEX IPO to Fund Bispecific Antibody Pipeline

China Unveils Elderly Nursing Plan to Boost 90% Nurse Coverage by 2027
Policy / Regulatory

China Unveils Elderly Nursing Plan to Boost 90% Nurse Coverage by 2027

Amgen’s Uplizna Scores Third FDA Indication in Myasthenia Gravis
CompanyDrug

Amgen’s Uplizna Scores Third FDA Indication in Myasthenia Gravis

Huadao Submits China CAR‑T Application for Refractory Lymphoma in $1B Market
CompanyDrug

Huadao Submits China CAR‑T Application for Refractory Lymphoma in $1B Market

Peijia Medical Wins NMPA Approval for TaurusTrio TAV, First Transfemoral System for Aortic Regurgitation
CompanyMedical Device

Peijia Medical Wins NMPA Approval for TaurusTrio TAV, First Transfemoral System for Aortic Regurgitation

Everest Medicines Licenses Lerodalcibep PCSK9 Inhibitor in $339M Greater China Deal
CompanyDeals

Everest Medicines Licenses Lerodalcibep PCSK9 Inhibitor in $339M Greater China Deal

Lilly's Retatrutide Achieves 28.7% Weight Loss in Phase 3 Obesity-Osteoarthritis Trial
CompanyDrug

Lilly’s Retatrutide Achieves 28.7% Weight Loss in Phase 3 Obesity-Osteoarthritis Trial

Joincare’s Pixavir Marboxil Wins NMPA Approval as First Single‑Dose Flu Treatment
CompanyDrug

Joincare’s Pixavir Marboxil Wins NMPA Approval as First Single‑Dose Flu Treatment

InduPro Secures Sanofi Investment and First Negotiation Rights on PD-1 Agonist Program
CompanyDeals

InduPro Secures Sanofi Investment and First Negotiation Rights on PD-1 Agonist Program

InnoCare's Zurletrectinib Wins NMPA Nod as China's First Next-Gen TRK Inhibitor
CompanyDrug

InnoCare’s Zurletrectinib Wins NMPA Nod as China’s First Next-Gen TRK Inhibitor

Brii Biosciences Taps OpenBench AI Platform to Accelerate Drug Discovery
CompanyDeals

Brii Biosciences Taps OpenBench AI Platform to Accelerate Drug Discovery

GSK Terminates Ideaya Synthetic Lethality Partnership, Returns Two Clinical Programs
CompanyDeals

GSK Terminates Ideaya Synthetic Lethality Partnership, Returns Two Clinical Programs